Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5172 + MK-8742 in chronic hepatitis C with chronic kidney disease
2013-003858-25Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of grazoprevir and verubecestat in chronic hepatitis C (CHC) (2 arms), sponsored by Merck & Co. Primary endpoint: SVR12 rate. Started Jan 2014; status: completed.
02
Drugs
grazoprevirverubecestat
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2013-003858-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003858-25.